A Phase 4 interventional study of ferric carboxymaltose and Normal saline 0.9% in Iron Deficiency and Heart Failure, sponsored by Vifor (International) Inc.. Completed at 16 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-18.
Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing ferric carboxymaltose in Iron Deficiencies — 8 open to participants now, 8 under way, 2 of them phase 3. ferric carboxymaltose · Iron Deficiencies.
Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, this one has the largest enrollment, is one of 3 that started in 2017, is one of 18 in phase 4, and was the 22nd registered.
386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.
Browse Iron Deficiencies studies →8 of the 40 studies testing ferric carboxymaltose in Iron Deficiencies are open now, in 7 countries. Recruiting first, the newest first:
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Ziekenhuis Oost-Limburg · Sites in Belgium
Ages 18+
Columbia University · Sites in United States
Ages 10–19
Erasmus Medical Center · Sites in Netherlands
Ages 65+
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Ages 18+
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 15 · Phase 4 18
First in 2007; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,132 is above the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 134 across the 40 interventional studies. Of the 31 that completed or were terminated, 2 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Vifor (International) Inc., one of the names counted as CSL Limited. Under that name alone:
Vifor (International) Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
CSL Limited has 9 studies filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
3 of the studies testing ferric carboxymaltose in Iron Deficiencies that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217873Phase 3Columbia UniversityIntraVenous Iron in Kids With Iron Deficiency and Scoliosis Study | 2027-08-31 |
| NCT05793996Tomsk National Research Medical Center of the Russian Academy of SciencesThe Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF) | 2026-12 |
| NCT05759078Wroclaw Medical UniversityEffect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 40 studies testing ferric carboxymaltose in Iron Deficiencies, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency (Affirm-AHF)
This is a randomised, double-blind, placebo-controlled Trial (RCT). The 52 weeks observation period following randomisation is considered appropriate to investigate the primary endpoint of recurrent HF hospitalisations and CV death. To evaluate the effect of intravenous ferric carboxymaltose (IV FCM) in iron deficient subjects with AHF, subjects will be enrolled during a hospital stay (Index hospitalisation) after the acute care treatment of the index event has been stabilised. All subjects will continue to receive their established standard therapy for HF and medical emergencies will be treated according to local routine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Currently hospitalised for an episode of acute heart failure (AHF) where AHF was the primary reason for hospitalisation. All of the following (i.e., items a to d) must apply:
Exclusion Criteria:
Subject has a significant medical condition(s), anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject, or may interfere with study assessments, outcomes, or the ability to provide written or comply with study procedures, in the Investigator's opinion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The first dose of study treatment will be administered for all randomised subjects while the patient is still hospitalised for the Index hospitalisation. The subsequent administrations of study treatment will be done as part of the outpatient clinic visits.
Drug: ferric carboxymaltose
The first dose of study treatment will be administered for all randomised subjects on the same day as randomisation.
Other: Normal saline 0.9%
FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
Also known as: Injectafer, Ferinject, Renegy, Iroprem
Normal saline will be administered as a bolus injection.
HF Hospitalizations and CV Death
HF = Heart Failure, CV = Cardiovascular. The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.
Time frame: up to 52 weeks after randomization
Recurrent CV Hospitalisations and CV Death
CV = Cardiovascular The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.
Time frame: up to 52 weeks after randomization
HF Hospitalisations
HF = Heart Failure HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.
Time frame: up to 52 weeks after randomisation
CV Mortality
CV = Cardiovascular CV mortality analysed as time to first event at 52 weeks after randomisation.
Time frame: at 52 weeks after randomisation.
Composite of HF Hospitalisations or CV Death
HF = Heart Failure, CV = Cardiovascular Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.
Time frame: at 52 weeks after randomisation
Days Lost Due to HF Hospitalisation or CV Death
HF = Heart Failure, CV = Cardiovascular Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.
Time frame: at 52 weeks after randomisation
HF Hospitalisations
HF = Heart Failure Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation
Time frame: up to 52 weeks after randomisation
CV Hospitalisations
CV = Cardiovascular Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation
Time frame: up to 52 weeks after randomisation
All-cause Mortality
Number of participants who died up to 52 weeks after randomisation
Time frame: up to 52 weeks after randomisation
Change From Baseline in NYHA Functional Class
NYHA = New York Heart Association NYHA functional class was assessed as Class I, II, III, IV or V: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit. Class V - Imputed for participants who died. Lower response categories are better for score NYHA.
Time frame: at 6, 12, 24 and 52 weeks after randomisation
Change From Baseline in the EQ-5D-5L Questionnaire Indexed Value
EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).
Time frame: at 6, 24 and 52 weeks after randomisation
KCCQ-12 Repeated-Measures Model for Analysis of Treatment Difference
KCCQ = Kansas City Cardiomyopathy Questionnaire The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.
Time frame: up to 52 weeks after randomisation
| Milestone | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Started | 567 | 565 |
| Started treatment | 559 | 551 |
| Completed | 427 | 437 |
| Not completed | 140 | 128 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Death | 98 | 95 |
| Withdrew: Lost to follow-up | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Protocol violation | 6 | 10 |
| Withdrew: Withdrawal by subject | 27 | 15 |
| Withdrew: Other | 8 | 5 |
HF = Heart Failure, CV = Cardiovascular. The composite of recurrent HF hospitalizations and CV death up to 52 weeks after randomization Total hospitalisations included first and recurrent events. If a participant was hospitalised for heart failure and died within 24 h from any cardiovascular event, this was counted as one event.
| Events | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 293 | 372 |
| Covid-19 Sensitivity Analysis | 274 | 363 |
CV = Cardiovascular The composite of recurrent CV hospitalisations and CV death at 52 weeks after randomisation Total hospitalisations included first and recurrent events. If a participant was hospitalised for a cardiovascular reason and died within 24 h of admission from any cardiovascular event, this was counted as one event.
| Events | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 370 | 451 |
| COVID-19 sensitivity analyses | 350 | 440 |
HF = Heart Failure HF hospitalisations up to 52 weeks after randomisation analysed as recurrent event.
| Events | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 217 | 294 |
| COVID-19 sensitivity analyses | 202 | 287 |
CV = Cardiovascular CV mortality analysed as time to first event at 52 weeks after randomisation.
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 77 | 78 |
| COVID-19 sensitivity analyses | 73 | 76 |
HF = Heart Failure, CV = Cardiovascular Analysed as time to first event at 52 weeks after randomisation. The number of participants with at least one HF Hospitalisation or CV Death is presented below.
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 181 | 209 |
| COVID-19 sensitivity analyses | 175 | 205 |
HF = Heart Failure, CV = Cardiovascular Number of days lost due to heart failure hospitalisations or cardiovascular death corresponds to the total number of days in hospital for heart failure from randomisation to last known date. Days lost due to cardiovascular death are added to the number of days lost due to heart failure hospitalisation.
| days | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Full Analysis Set (FAS) | 3.8 ± 9.06 | 6.2 ± 14.48 |
| COVID-19 sensitivity analyses | 3.5 ± 8.18 | 6.1 ± 14.42 |
HF = Heart Failure Number of participants with at least one HF Hospitalisation up to 52 weeks after randomisation
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| HF Hospitalisations | 142 | 178 |
CV = Cardiovascular Number of participants with at least one CV Hospitalisation up to 52 weeks after randomisation
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| CV Hospitalisations | 181 | 220 |
Number of participants who died up to 52 weeks after randomisation
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| All-cause Mortality | 98 | 96 |
NYHA = New York Heart Association NYHA functional class was assessed as Class I, II, III, IV or V: Class I - No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath when walking, climbing stairs etc. Class II - Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity. Class III - Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g. walking short distances (20-100 m). Comfortable only at rest. Class IV - Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients. If a participant was hospitalised at any point during any post-baseline visit and did not have any NYHA assessment for this visit, then Class IV was to be imputed for the visit. Class V - Imputed for participants who died. Lower response categories are better for score NYHA.
| Participants | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Baseline — Class I | 14 | 8 |
| Baseline — Class II | 255 | 240 |
| Baseline — Class III | 272 | 277 |
| Baseline — Class IV | 16 | 22 |
| Baseline — Class V | 0 | 0 |
| Week 6 — Class I | 38 | 38 |
| Week 6 — Class II | 296 | 271 |
| Week 6 — Class III | 151 | 151 |
| Week 6 — Class IV | 13 | 31 |
| Week 6 — Class V | 18 | 23 |
| Week 12 — Class I | 39 | 40 |
| Week 12 — Class II | 296 | 267 |
| Week 12 — Class III | 107 | 131 |
| Week 12 — Class IV | 14 | 18 |
| Week 12 — Class V | 36 | 32 |
| Week 24 — Class I | 47 | 47 |
| Week 24 — Class II | 288 | 265 |
| Week 24 — Class III | 88 | 100 |
| Week 24 — Class IV | 13 | 20 |
| Week 24 — Class V | 56 | 63 |
| Week 52 — Class I | 48 | 53 |
| Week 52 — Class II | 234 | 223 |
| Week 52 — Class III | 61 | 75 |
| Week 52 — Class IV | 7 | 17 |
| Week 52 — Class V | 99 | 95 |
EQ-5D-5L: European Quality of Life-5 Dimensions-5 Levels The EQ 5D questionnaire consists of a health descriptive system for participants to self-classify and rate their health status on the day of administration. The descriptive system includes 5 items/dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression, which are coded from 1 (best state) to 5 (worst state).
| Change from baseline in EQ-5D-5L | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Week 6 | 0.05 ± 0.01 | 0.03 ± 0.01 |
| Week 24 | 0.06 ± 0.01 | 0.05 ± 0.01 |
| Week 52 | 0.06 ± 0.01 | 0.06 ± 0.01 |
KCCQ = Kansas City Cardiomyopathy Questionnaire The KCCQ 12 is a health-related quality of life questionnaire for Heart Failure. It is a 12 item questionnaire that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge and Quality of life. Scores are generated for each domain and scaled from 0 to 100, with 0 denoting the lowest reportable health status and 100 the highest reportable health status.
| KCCQ-12 score | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Week 2 | 18.53 ± 1.16 | 17.24 ± 1.19 |
| Week 4 | 21.26 ± 1.18 | 18.36 ± 1.21 |
| Week 6 | 23.49 ± 1.20 | 19.88 ± 1.23 |
| Week 12 | 25.57 ± 1.24 | 21.88 ± 1.26 |
| Week 24 | 26.30 ± 1.26 | 23.32 ± 1.27 |
| Week 36 | 25.78 ± 1.28 | 23.70 ± 1.30 |
| Week 52 | 25.75 ± 1.33 | 24.31 ± 1.34 |
Collected over During treatment period up to 52 weeks after randomization. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 - FCM (Ferric Carboxymaltose) | 99/559 (17.7%) | 250/559 (44.7%) | 51/559 (9.1%) |
| Group 2 - Placebo (Normal Saline (NaCl 0.9%)) | 96/551 (17.4%) | 282/551 (51.2%) | 45/551 (8.2%) |
| Event | Group 1 - FCM (Ferric Carboxymaltose) | Group 2 - Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Cardiac failureCardiac disorders | 116/559 | 127/551 |
| Cardiac failure congestiveCardiac disorders | 20/559 | 23/551 |
| Cardiac failure acuteCardiac disorders | 21/559 | 17/551 |
| PneumoniaInfections and infestations | 11/559 | 15/551 |
| DeathGeneral disorders | 8/559 | 13/551 |
| Cardiac arrestCardiac disorders | 8/559 | 11/551 |
| Atrial fibrillationCardiac disorders | 10/559 | 4/551 |
| SepsisInfections and infestations | 7/559 | 9/551 |
| Acute myocardial infarctionCardiac disorders | 2/559 | 8/551 |
| Pulmonary congestionRespiratory, thoracic and mediastinal disorders | 1/559 | 8/551 |
| Event | Group 1 - FCM (Ferric Carboxymaltose) | Group 2 - Placebo (Normal Saline (NaCl 0.9%)) |
|---|---|---|
| Cardiac failureCardiac disorders | 51/559 | 45/551 |
| Age, Customized(Participants) | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 and 64 years | 139 | 142 | 281 |
| Between 65 and 84 years | 369 | 370 | 739 |
| ≥ 85 years | 51 | 39 | 90 |
| Sex: Female, Male(Participants) | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) | Total |
|---|---|---|---|
| Female | 244 | 250 | 494 |
| Male | 315 | 301 | 616 |
| Ethnicity (NIH/OMB)(Participants) | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) | Total |
|---|---|---|---|
| Hispanic or Latino | 51 | 50 | 101 |
| Not Hispanic or Latino | 498 | 489 | 987 |
| Unknown or Not Reported | 10 | 12 | 22 |
| Region of Enrollment(Participants) | FCM (Ferric Carboxymaltose) | Placebo (Normal Saline (NaCl 0.9%)) | Total |
|---|---|---|---|
| Argentina | 24 | 24 | 48 |
| Brazil | 14 | 14 | 28 |
| Croatia | 39 | 43 | 82 |
| Georgia | 98 | 95 | 193 |
| Israel | 41 | 38 | 79 |
| Italy | 55 | 58 | 113 |
| Lebanon | 16 | 16 | 32 |
| Netherlands | 38 | 31 | 69 |
| Poland | 90 | 90 | 180 |
| Romania | 76 | 78 | 154 |
| Singapore | 23 | 22 | 45 |
| Spain | 12 | 12 | 24 |
| Sweden | 4 | 1 | 5 |
| Ukraine | 23 | 23 | 46 |
| United Kingdom | 6 | 6 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Jul 2020, 39 months.
Results were first posted in Jun 2021, 10 months after primary completion.
Of 26 phase 4 interventional studies under Iron Deficiencies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's 39 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose